Cyprotex PLC provides in vitro and in silico absorption, distribution, metabolism, excretion, and toxicity/ pharmacokinetic (ADMET and PK) information services. Its ADME and PK services include in vitro metabolism, in vitro permeability and transporters, polymorphic and non-CYP mediated metabolism, protein binding, bioanalysis, and prodrug services; and toxicology services comprise multiparametric toxicity, cardiotoxicity, neurotoxicity, 3D microtissue, custom toxicology, mechanistic toxicity, custom toxicology, mechanistic toxicity, drug-drug interaction, genotoxicity assays, endocrine disruption, and in vitro dermal and eye irritation services. The company also provides biosciences services, including exploratory biology and mechanistic studies, and custom assay design and development services; and in vitro dermal and eye testing services, such as dermal and ocular assays, and skin sensitization assays. In addition, it offers endocrine disruption screening programs and assays. Further, the company provides chemPK, a workflow-based solution that predicts human pharmacokinetic parameters directly from chemical structure using a physiologically based pharmacokinetic (PBPK) modelling approach; chemTox, a solution for prediction of toxicity from chemical structure; Cloe PK, which uses PBPK to predict pharmacokinetic simulation; Cloe HIA that uses physiological modelling to predict human intestinal absorption; and Cyprotex Discovery Bus, an IT solution for the drug discovery industry. Additionally, it offers physicochemical profiling services, including turbidimetric and thermodynamic solubility, chemical stability, pKa, and lipophilicity. It serves various industries, including pharmaceutical, biotechnology, cosmetics, personal care, agrochemical, chemical industries, and academia in the United Kingdom, rest of Europe, North America, and internationally. The company was founded in 1999 and is headquartered in Macclesfield, the United Kingdom. As of December 14, 2016, Cyprotex plc operates as a subsidiary of Evotec AG.